All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
about
IDH1 and IDH2 mutations in gliomasGenetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 MutationIn vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesModern brain tumor imagingMetabolic consequences of oncogenic IDH mutationsThe epidemiology of glioma in adults: a "state of the science" reviewThe global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for gliomaRecursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsInternational retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.IDH mutations: genotype-phenotype correlation and prognostic impact.Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.1p/19q testing has no significance in the workup of glioblastomas.Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.Glial progenitors as targets for transformation in glioma.Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cellsIDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.How molecular testing can help (and hurt) in the workup of gliomas.TCF12 is mutated in anaplastic oligodendrogliomaIndications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Intramedullary pilomyxoid astrocytoma with intracerebral metastasis exhibiting oligoden-droglioma-like featuresIsocitrate dehydrogenase mutations in gliomasAdult brainstem gliomas: Correlation of clinical and molecular features.What do we know about IDH1/2 mutations so far, and how do we use it?Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologiesInherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in gliomaIsocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomasN-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cellsMitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade.Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
P2860
Q24561928-F08AEFE6-6390-4F53-8BD0-3A90429D16FDQ26767392-FBA6E739-3E9D-4933-BB9B-F058F8601D59Q26820289-C67B7A16-9C2C-42CE-AD62-662EF87D78E8Q27002344-B83FBFB2-965D-48FC-8A4C-F536483310C7Q28082949-FA9AC966-ED62-44D4-923C-28ACE3EF95E4Q28387839-35D0E738-ECE6-4449-A3C4-4E1BE585E32AQ28741768-A670D2ED-433D-491D-9A5E-E159298DBDB0Q30370204-3C2A14DB-568B-4E85-8B8F-4FC9D9971C7BQ30426724-9F142899-5C43-47BF-BA6C-9BE3B6F758DEQ30836702-F3A31668-BE8F-469A-A490-6BE07B885395Q33615867-076F0761-4D2C-48A2-A1DB-CCE10C873800Q33859265-DD97FF7C-7453-401C-A7D6-A96294FBFC2DQ33893445-F1ED2057-4F3F-481D-A5F3-608E13CF84B7Q33894486-7606D164-3201-437D-BACC-CF95D670B7E5Q34062043-E91A333F-83E2-43AC-B02F-F23718937B1DQ34446905-08CA73C3-A442-4DF9-9748-F24AC82304DEQ34695556-C94F74CF-5B70-4C30-BDC4-8718EBAE0ED1Q34735661-124307A3-2BAA-4423-B69E-E74A24171802Q35006426-FC1063BD-4BC4-42DC-A380-D9CF80DD650FQ35053662-9C598AD2-350F-4324-9D96-C3F7DEFE226EQ35204658-A005D529-073F-41D1-8F75-E947612FF00CQ35634042-640CA003-01D4-4E64-8922-864DD16BFB02Q35770275-82E7F047-BA47-4483-BA4E-368AF5AECB50Q35813648-97B25499-875B-4D06-AB10-511091E724C2Q36037100-43D89B31-E81F-4488-83BE-BCFA5B454E68Q36106223-BEDB6B7B-88C3-4AC3-A79B-02307A0F95CAQ36367409-8D15B65F-F7D8-4249-A076-004360CDF2B9Q36663080-80CE24CA-15C2-4DD4-9DF2-EB053A9E8C76Q36788229-FC40D684-17BC-48A7-9C78-0D56C0613130Q36792720-CA0FCC44-0F4C-4DFE-868B-2E68482E61A1Q36792729-9B9C6FC3-167C-4109-98A1-9F185501AB58Q36809370-E2E971DE-4856-4FB0-9220-79530525C0F9Q36925070-0CF5F7D1-5DF9-4790-A02D-5C72299C6233Q37151094-04ABD597-1757-4AD6-9FE2-6EF1503F0D2CQ37187689-2FF27052-6B69-4AC2-84CE-0142E1BDE940Q37429161-9A57DAF1-2D13-45E1-AE5D-AC00AB4FBAF9Q37580501-E59EAB05-DCD1-420B-B4F4-F3BA3CA5E5DEQ37613957-199649BF-F9BB-48C7-B988-6E12436BCB46Q37627927-8F8C1107-60E5-4AB9-A839-68333FB63F5AQ37662100-7AA752CB-380F-4160-84F4-7FCA45AC4ADB
P2860
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@en
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@nl
type
label
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@en
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@nl
prefLabel
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@en
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@nl
P2093
P1433
P1476
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
@en
P2093
B Boisselier
C Carpentier
E Crinière
J Laffaire
J-Y Delattre
K Hoang-Xuan
K Mokhtari
P304
P356
10.1212/WNL.0B013E3181E1CF3A
P407
P577
2010-04-28T00:00:00Z